Contemporary bladder cancer

Variant histology may be a significant driver of disease

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: To evaluate pathologic and survival outcomes among patients with variant histology (VH) urothelial carcinoma of the bladder. Methods: A retrospective review of an institutional database was performed to identify all patients who underwent radical cystectomy with curative intent for urothelial carcinoma between 2008 and June 2013. VH was assigned by genitourinary pathologists. Descriptive statistics comparing clinicopathologic outcomes were performed using the Pearson chi-square test and analysis of variance. Survival was evaluated using the Kaplan-Meier methodology and the Cox proportional hazards regression. Results: In total, 624 patients were identified. Overall, 26% (. n = 162) had VH, with the most common being squamous differentiation (. n = 68), micropapillary variant (MPV, n = 28), plasmacytoid variant (PCV, n = 25), and sarcomatoid variant (. n = 15); 64% of MPV and 72% of PCV had positive lymph nodes. Compared with 8% of patients with a non VH, 44% of those with VH were categorized as pT4 (. P<0.001). MPV and PCV were independently associated with twice the risk of all-cause mortality compared with nonvariant, when adjusting for demographics, American Society of Anesthesiologists class, transurethral resection of bladder tumor stage, cystectomy stage, positive lymph nodes, and reception of chemotherapy (odds ratio = 2.20, 95% CI: 1.28-3.78; P = 0.004; odds ratio = 2.42, 95% CI: 1.33-4.42; P = 0.004, respectively). There was no difference in risk of mortality associated with squamous differentiation or sarcomatoid variant (. P>0.05 each). Conclusions: MPV and PCV are associated with increased risk of mortality. Improved recognition of VH will enable larger cohorts of study and better prognostic understanding of the significance of specific VH involvement.

Original languageEnglish
Pages (from-to)18.e15-18.e20
JournalUrologic Oncology: Seminars and Original Investigations
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Urinary Bladder Neoplasms
Histology
Carcinoma
Survival
Cystectomy
Chi-Square Distribution
Analysis of Variance
Urinary Bladder
Cohort Studies
Lymph Nodes
Databases
Mortality

Keywords

  • Clinical outcomes
  • Radical cystectomy
  • Survival
  • Urothelial bladder cancer
  • Variant histology

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{48226606cec3427d9a1ca4a67af7fcbf,
title = "Contemporary bladder cancer: Variant histology may be a significant driver of disease",
abstract = "Objectives: To evaluate pathologic and survival outcomes among patients with variant histology (VH) urothelial carcinoma of the bladder. Methods: A retrospective review of an institutional database was performed to identify all patients who underwent radical cystectomy with curative intent for urothelial carcinoma between 2008 and June 2013. VH was assigned by genitourinary pathologists. Descriptive statistics comparing clinicopathologic outcomes were performed using the Pearson chi-square test and analysis of variance. Survival was evaluated using the Kaplan-Meier methodology and the Cox proportional hazards regression. Results: In total, 624 patients were identified. Overall, 26{\%} (. n = 162) had VH, with the most common being squamous differentiation (. n = 68), micropapillary variant (MPV, n = 28), plasmacytoid variant (PCV, n = 25), and sarcomatoid variant (. n = 15); 64{\%} of MPV and 72{\%} of PCV had positive lymph nodes. Compared with 8{\%} of patients with a non VH, 44{\%} of those with VH were categorized as pT4 (. P<0.001). MPV and PCV were independently associated with twice the risk of all-cause mortality compared with nonvariant, when adjusting for demographics, American Society of Anesthesiologists class, transurethral resection of bladder tumor stage, cystectomy stage, positive lymph nodes, and reception of chemotherapy (odds ratio = 2.20, 95{\%} CI: 1.28-3.78; P = 0.004; odds ratio = 2.42, 95{\%} CI: 1.33-4.42; P = 0.004, respectively). There was no difference in risk of mortality associated with squamous differentiation or sarcomatoid variant (. P>0.05 each). Conclusions: MPV and PCV are associated with increased risk of mortality. Improved recognition of VH will enable larger cohorts of study and better prognostic understanding of the significance of specific VH involvement.",
keywords = "Clinical outcomes, Radical cystectomy, Survival, Urothelial bladder cancer, Variant histology",
author = "Monn, {M. Francesca} and Hristos Kaimakliotis and Pedrosa, {Jose A.} and Cary, {K. Clinton} and Richard Bihrle and Liang Cheng and Michael Koch",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2014.10.001",
language = "English",
volume = "33",
pages = "18.e15--18.e20",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Contemporary bladder cancer

T2 - Variant histology may be a significant driver of disease

AU - Monn, M. Francesca

AU - Kaimakliotis, Hristos

AU - Pedrosa, Jose A.

AU - Cary, K. Clinton

AU - Bihrle, Richard

AU - Cheng, Liang

AU - Koch, Michael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: To evaluate pathologic and survival outcomes among patients with variant histology (VH) urothelial carcinoma of the bladder. Methods: A retrospective review of an institutional database was performed to identify all patients who underwent radical cystectomy with curative intent for urothelial carcinoma between 2008 and June 2013. VH was assigned by genitourinary pathologists. Descriptive statistics comparing clinicopathologic outcomes were performed using the Pearson chi-square test and analysis of variance. Survival was evaluated using the Kaplan-Meier methodology and the Cox proportional hazards regression. Results: In total, 624 patients were identified. Overall, 26% (. n = 162) had VH, with the most common being squamous differentiation (. n = 68), micropapillary variant (MPV, n = 28), plasmacytoid variant (PCV, n = 25), and sarcomatoid variant (. n = 15); 64% of MPV and 72% of PCV had positive lymph nodes. Compared with 8% of patients with a non VH, 44% of those with VH were categorized as pT4 (. P<0.001). MPV and PCV were independently associated with twice the risk of all-cause mortality compared with nonvariant, when adjusting for demographics, American Society of Anesthesiologists class, transurethral resection of bladder tumor stage, cystectomy stage, positive lymph nodes, and reception of chemotherapy (odds ratio = 2.20, 95% CI: 1.28-3.78; P = 0.004; odds ratio = 2.42, 95% CI: 1.33-4.42; P = 0.004, respectively). There was no difference in risk of mortality associated with squamous differentiation or sarcomatoid variant (. P>0.05 each). Conclusions: MPV and PCV are associated with increased risk of mortality. Improved recognition of VH will enable larger cohorts of study and better prognostic understanding of the significance of specific VH involvement.

AB - Objectives: To evaluate pathologic and survival outcomes among patients with variant histology (VH) urothelial carcinoma of the bladder. Methods: A retrospective review of an institutional database was performed to identify all patients who underwent radical cystectomy with curative intent for urothelial carcinoma between 2008 and June 2013. VH was assigned by genitourinary pathologists. Descriptive statistics comparing clinicopathologic outcomes were performed using the Pearson chi-square test and analysis of variance. Survival was evaluated using the Kaplan-Meier methodology and the Cox proportional hazards regression. Results: In total, 624 patients were identified. Overall, 26% (. n = 162) had VH, with the most common being squamous differentiation (. n = 68), micropapillary variant (MPV, n = 28), plasmacytoid variant (PCV, n = 25), and sarcomatoid variant (. n = 15); 64% of MPV and 72% of PCV had positive lymph nodes. Compared with 8% of patients with a non VH, 44% of those with VH were categorized as pT4 (. P<0.001). MPV and PCV were independently associated with twice the risk of all-cause mortality compared with nonvariant, when adjusting for demographics, American Society of Anesthesiologists class, transurethral resection of bladder tumor stage, cystectomy stage, positive lymph nodes, and reception of chemotherapy (odds ratio = 2.20, 95% CI: 1.28-3.78; P = 0.004; odds ratio = 2.42, 95% CI: 1.33-4.42; P = 0.004, respectively). There was no difference in risk of mortality associated with squamous differentiation or sarcomatoid variant (. P>0.05 each). Conclusions: MPV and PCV are associated with increased risk of mortality. Improved recognition of VH will enable larger cohorts of study and better prognostic understanding of the significance of specific VH involvement.

KW - Clinical outcomes

KW - Radical cystectomy

KW - Survival

KW - Urothelial bladder cancer

KW - Variant histology

UR - http://www.scopus.com/inward/record.url?scp=84922659573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922659573&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.10.001

DO - 10.1016/j.urolonc.2014.10.001

M3 - Article

VL - 33

SP - 18.e15-18.e20

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -